drugset / Trial / NCT01166217
A Single Dose Study Of PF-04620110 In Healthy Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the relative bioavailability of three different oral dose formulations of PF-04620110.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04620110 | Small molecule | 5 mg | Oral |
Indications
No indication recorded.